Predictive Oncology Inc. (NASDAQ:POAI) announced that it has completed a multi-year study with UPMC Magee-Womens Hospital in Pittsburgh.
The science-driven company said the objective of the study was to evaluate the use of artificial intelligence (AI) to build multi-omic machine learning (ML) models and test if these models can learn associations between the datasets and ovarian cancer patient short- and long-term survival.
"Ultimately, these models could support the tailoring of therapies to individual patients with the goal of positively affecting the overall survival of ovarian cancer patients," Predictive Oncology CEO Raymond Vennare said in a statement.
"These findings were only made possible because of the substantial resources at our disposal, including a robust machine learning platform, the use of digital pathology, access to an extensive biobank of cryopreserved tumor samples and our considerable scientific expertise," he added.
Predictive Oncology noted its multi-omic machine learning models have the potential to overcome the gap defining the prognostic subgroups within ovarian cancer.
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide.
Contact Sean at sean@proactiveinvestors.com